References
- Danckert B, Ferlay J, Engholm G, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 (26.03.2019). Association of the Nordic Cancer Registries. Danish Cancer Society; 2019 [accessed 2020 Jun 19]. Available from: http://www.ancr.nu
- Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 update. Eur Urol. 2020;79:62–79.
- Engholm G, Ferlay J, Christensen N, et al. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49:725–736.
- Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39:42–45.
- Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
- CPR, Det Centrale Personregister. Udlevering af oplysninger. [accessed 2020 Aug 4]. Available from: https://cpr.dk/spoergsmaal-og-svar/udlevering-af-oplysninger/
- Pottegård A, Schmidt SA, Wallach-Kildemoes H, et al. Data Resource Profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798–798.
- Sundhedsdatastyrelsen. Registre og services. Landsregisteret for Patologi (LRP). [updated 2018 Mar 27]. Available from: https://sundhedsdatastyrelsen.dk/da/registre-og-services/om-de-nationale-sundhedsregistre/doedsaarsager-og-biologisk-materiale/patologiregisteret
- Bakken IJ, Gystad SO, Christensen Oo, et al. Comparison of data from the Norwegian Patient Register and the Cancer Registry of Norway. Tidsskr nor Laegeforen. 2012;132:1336–1340.
- Pukkala E, Engholm G, Højsgaard Schmidt LK, et al. Nordic Cancer Registries – an overview of their procedures and data comparability. Acta Oncol. 2018;57:440–455.
- Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45:1218–1231.
- Socialstyrelsen. The Swedish Cancer Register. [accessed 2020 Jun 17]. Available from: https://www.socialstyrelsen.se/en/statistics-and-data/registers/register-information/swedish-cancer-register/
- Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol. 1994;33:365–369.
- Leinonen MK, Miettinen J, Heikkinen S, et al. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J Cancer. 2017;77:31–39.
- Sigurdardottir LG, Jonasson JG, Stefansdottir S, et al. Data quality at the Icelandic Cancer Registry: comparability, validity, timeliness and completeness. Acta Oncol. 2012;51:880–889.
- Hansen E, Larsson H, Norgaard M, et al. The Danish Bladder Cancer Database. Clin Epidemiol. 2016;8:439–443.
- Dansk Blaere Cancer Database (DaBlaCa-Data), National årsrapport 2018. 2019 Apr [accessed 2020 May 27]. Available from: https://www.sundhed.dk/content/cms/86/15686_dablaca_anonymiseret_2018.pdf
- Haggstrom C, Liedberg F, Hagberg O, et al. Cohort profile: the Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). BMJ Open. 2017;7:e016606.
- Regionalt Cancercentrum Stockholm Gotland, Urinblåsa och urinvägar, kvalitetsregister. [accessed 2020 Jun 2]. Available from: https://www.cancercentrum.se/stockholm-gotland/cancerdiagnoser/urinblasa-urinvagar/kvalitetsregister/dokument/
- Salminen AP, Koskinen I, Perez IM, et al. Neoadjuvant chemotherapy does not increase the morbidity of radical cystectomy: a 10-year retrospective nationwide study. Eur Urol Oncol. 2018;1:525–530.
- Salminen AP, Perez IM, Klén R, et al. Adverse events during neoadjuvant chemotherapy for muscle invasive bladder cancer. BLC. 2019;5:273–279.
- Icelandic Cancer Registry, Urinary tract. [accessed 2020 Aug 12]. Available from: https://www.krabb.is/krabbameinsskra/en/cancer-sites/cancers-a-z/urinary-tract/
- Liedberg F, Hagberg O, Holmäng s, et al. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scand J Urol. 2015;49:290–295.
- Cancer Registry of Norway. Cancer in Norway 2017 – Cancer incidence, mortality, survival and prevalence in Norway. [accessed 2020 Jun 2]. Available from: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2017/cin-2017.pdf
- Jerlström T. Personal Communication; 2020.
- SEER*Stat Databases: SEER Incidence Data, 1975–2017. [accessed 2020 May 28]. Available from: https://seer.cancer.gov/data/
- Al-Husseini MJ, Kunbaz A, Saad AM, et al. Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis. BMC Cancer. 2019;19:46.
- SEER*Stat Databases: November 2019. Submission. [accessed 2020 May 27]. Available from: https://seer.cancer.gov/data-software/documentation/seerstat/nov2019/
- Cheluvappa R, Smith DP, Cerimagic S, et al. A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. Int Urol Nephrol. 2014;46:1351–1360.
- Ripping TM, Kiemeney LA, van Hoogstraten LMC, BlaZIB Study Group, et al. Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB). BMC Cancer. 2020;20:455.
- Andreassen BK, Aagnes B, Gislefoss R, et al. Incidence and survival of urothelial carcinoma of the urinary bladder in Norway 1981–2014. BMC Cancer. 2016;16:799.
- Dansk Blaere Cancer Database (DaBlaCa-Data), Årsrapport 2015. February 1, 2016. [accessed 2020 Nov 10]. Available from: https://www.sundhed.dk/content/cms/86/15686_dablacadata_1–%C3%A5rsrapport_2015_til_offentligg%C3%B8relse.pdf
- Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48:27–33.